Lessons from the Oncology Clinic: Repurposing PI3K Pathway Inhibitors for the Treatment of PTEN Hamartoma Tumor...

Area of Science:

• Genetics
• Oncology
• Cell Biology

Background:

• PTEN hamartoma tumor syndrome (PHTS) is a genetic disorder characterized by significant phenotypic variation among patients.
• The precise genetic mechanisms driving this variation remain largely unknown.
• Understanding these abnormalities is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the underlying genetic causes of phenotypic diversity in PTEN hamartoma tumor syndrome (PHTS).
• To investigate the role of PTEN gene alterations in endothelial cells within PHTS.
• To identify potential therapeutic targets for PHTS-associated vascular malformations.

Main Methods:

• Analysis of genetic abnormalities in PHTS patients.
• Investigation of somatic loss of PTEN via copy-neutral loss of heterozygosity.
• Examination of uniparental disomy in endothelial cells.
• Assessment of response to PI3K/AKT/mTOR pathway inhibitors.

Main Results:

• Somatic loss of the PTEN gene, specifically through copy-neutral loss of heterozygosity, was identified as a key genetic event.
• This genetic alteration leads to uniparental disomy in endothelial cells.
• The resulting vascular malformations in PHTS patients demonstrated a positive response to PI3K/AKT/mTOR pathway inhibitors.

Conclusions:

• Somatic PTEN loss and subsequent uniparental disomy in endothelial cells contribute to vascular malformations in PHTS.
• These findings highlight the therapeutic potential of targeting the PI3K/AKT/mTOR pathway in PHTS.
• This study provides critical insights into the genetic basis of PHTS and offers a promising therapeutic avenue.